EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.755
https://www.valueinhealthjournal.com/article/S1098-3015(22)02959-X/fulltext
Title :
EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02959-X&doi=10.1016/j.jval.2022.09.755
First page :
Section Title :
Open access? :
No
Section Order :
10295